



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

MAINTENANCE OF CERTIFICATION EXAMINATION IN ADDICTION PSYCHIATRY

2019 Content Blueprint
(September 18, 2018)

| | | |
|---------------------------------|--|-------------|
| Number of questions: 150 | | |
| 01. | Scientific foundations of addiction psychiatry | 9–11% |
| 02. | Evaluation | 23–27% |
| 03. | Treatment | 55–65% |
| 04. | Systems-based practice | 4–6% |
| TOTAL | | 100% |

Note: A more detailed content outline is shown below.

MAINTENANCE OF CERTIFICATION EXAMINATION IN ADDICTION PSYCHIATRY 2019 Content Outline

| | |
|------------|---|
| 01. | Scientific foundations of addiction psychiatry |
| | A. Epidemiology |
| | B. Genetics |
| | C. Behavior |
| | D. Pharmacology |
| | 1. Alcohol |
| | 2. Sedatives, hypnotics, anxiolytics |
| | 3. Cocaine and stimulants |
| | 4. Opioids |
| | 5. Cannabinoids |
| | 6. Tobacco/nicotine |
| | 7. PCP, hallucinogens, and inhalants |
| | 8. Caffeine |
| | 9. Other |
| | E. Neurobiology |
| | F. Other |
| 02. | Evaluation |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| | |
|------------|--|
| A. | Screening |
| B. | Comprehensive assessment and diagnosis |
| 1. | DSM diagnostic criteria |
| 2. | Signs and symptoms of intoxication and withdrawal |
| a. | Alcohol |
| b. | Sedatives, hypnotics, anxiolytics |
| c. | Cocaine and stimulants |
| d. | Opioids |
| e. | Cannabinoids |
| f. | Tobacco/nicotine |
| g. | PCP, hallucinogens, and inhalants |
| h. | Caffeine |
| i. | Other |
| 3. | Comorbidity |
| a. | Psychiatric |
| b. | Medical |
| 4. | Other |
| C. | Laboratory testing |
| D. | Psychometric testing |
| 03. | Treatment |
| A. | Pharmacotherapy |
| 1. | Management of intoxication (toxicity) and withdrawal |
| a. | Alcohol |
| b. | Sedatives, hypnotics, anxiolytics |
| c. | Cocaine and stimulants |
| d. | Opioids |
| e. | Cannabinoids |
| f. | Tobacco/nicotine |
| g. | PCP, hallucinogens, and inhalants |
| h. | Other |
| 2. | Relapse prevention |
| a. | Alcohol |
| b. | Opioids |
| c. | Tobacco/nicotine |
| d. | Other |
| 3. | Management of co-occurring conditions |
| a. | Psychiatric |
| b. | Medical (including pain, HIV) |
| B. | Psychotherapy and psychosocial treatment |
| 1. | Brief intervention |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| | |
|------------|--|
| 2. | Motivational enhancement |
| 3. | Cognitive behavior therapy |
| 4. | Twelve-step facilitation |
| 5. | Behavioral/contingency management |
| 6. | Couples, family, and network therapies |
| 7. | Mutual help approaches |
| 8. | Other |
| C. | Other |
| 04. | Systems-based practice |
| A. | Special populations |
| 1. | Children and adolescents |
| 2. | Geriatric |
| 3. | Women (including pregnancy issues) |
| 4. | Professionals (e.g., health care workers, athletes, pilots) |
| 5. | Ethnic and cultural groups |
| 6. | Gay and lesbian |
| 7. | Homeless |
| 8. | Forensics/incarcerated patients |
| 9. | Other |
| B. | Legal issues (e.g., laws, regulations) |
| C. | Public health and prevention, and public policy |
| D. | Health services |
| E. | Ethics and professionalism (e.g., privacy and confidentiality) |